Regeneron Pharmaceuticals (REGN) is a US-listed Healthcare company in Biotechnology with a market capitalization of $67.0B, trading at $650.82 on the NASDAQ. This SniperIQ fundamentals page covers Regeneron Pharmaceuticals's valuation (P/E 15.3x, P/B 2.2x), profitability (net margin 29.6%), revenue (
4.3B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Market Cap$67.0B
P/E (TTM)15.3x
Net Margin29.6%
Revenue (FY25)
4.3B
Full research coverage
8-Quarter Revenue & Margin Trend
Debt Maturity & Coverage
Peer Valuation Comparison
Free Cash Flow & Owner Earnings
AI Signal + Institutional Flow
DCF Valuation Model
Frequently Asked Questions
What is Regeneron Pharmaceuticals's market cap?
Regeneron Pharmaceuticals (REGN) has a market capitalization of approximately $67.0B, trading at $650.82 on the NASDAQ. Market cap moves with the live share price.
What is Regeneron Pharmaceuticals's P/E ratio?
Regeneron Pharmaceuticals's trailing twelve-month P/E ratio is 15.3x, with a price-to-book (P/B) of 2.2x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals runs a net profit margin of 29.6%, a gross margin of 84.5%, and an operating margin of 24.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Regeneron Pharmaceuticals generate?
Regeneron Pharmaceuticals reported revenue of
4.3B for fiscal year 2025, with net income of $4.5B and earnings per share (EPS) of 43.07. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Regeneron Pharmaceuticals pay a dividend?
Regeneron Pharmaceuticals offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Regeneron Pharmaceuticals financially healthy?
Regeneron Pharmaceuticals carries a debt-to-equity ratio of 0.09x and a current ratio of 3.57x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Regeneron Pharmaceuticals a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Regeneron Pharmaceuticals (REGN) the key facts are: market cap $67.0B, P/E 15.3x, revenue
4.3B, 52-week range 541-821.11. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Regeneron Pharmaceuticals's full fundamentals live
Get Regeneron Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.